Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2010 Nov;33(11):686-92.
doi: 10.1002/clc.20814.

Long-term results following switch from abciximab to eptifibatide during percutaneous coronary intervention

Michael Koutouzis  1 , Bo Lagerqvist, Jonas Oldgren, Axel Akerblom, Magnus Wahlin, Thomas Karlsson, Per Albertsson, Göran Matejka, Lars Grip
Affiliations
Multicenter Study

Long-term results following switch from abciximab to eptifibatide during percutaneous coronary intervention

Michael Koutouzis et al. Clin Cardiol. 2010 Nov.

Abstract

Background: The usage of platelet glycoprotein (GP) IIb/IIIa receptor inhibitors improves the outcome during high-risk percutaneous coronary interventions (PCI). The aim of this study was to evaluate the long-term effects after a planned switch from abciximab to eptifibatide during PCI.

Hypothesis: A switch from the general use of abciximab to eptifibatide as a GP IIb/IIIa in connection with PCI would not have any negative effects on long-term clinical outcomes.

Methods: To reduce costs, a general switch from abciximab to eptifibatide was instituted in 2004 in 2 university hospitals in Sweden. All patients treated 6 months before and 6 months after the switch were followed for 30 months. During the study period, 1038 patients underwent PCI and received a GP IIb/IIIa receptor inhibitor, 481 (46%) before the switch (Group A) and 557 (54%) after the switch (Group B). The 2 groups had similar baseline characteristics. The primary endpoint was the composite of death, myocardial infarction, stroke, or new coronary revascularization (percutaneous or surgical); secondary endpoints were the individual components of this composite. A separate analysis was performed on patients treated for ST-segment elevation myocardial infarction, non-ST-segment elevation myocardial infarction/unstable angina, and diabetes, respectively. Data were collected from the Swedish Coronary Angiography and Angioplasty Registry.

Results: There were no differences between the groups in the primary endpoint (29.7% in Group A vs 29.3% in Group B; P = 0.48) or in any of the secondary endpoints.

Conclusions: A switch from the general usage of abciximab to eptifibatide as a GP IIb/IIIa receptor inhibitor in connection with PCI did not seem to have any negative effects on long-term clinical outcomes.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan‐Meier curves for any of the composites of the primary endpoint: (A) death, (B) new AMI, (C) stroke, and (D) new revascularization. Abbreviations: AMI, acute myocardial infarction
Figure 2
Figure 2
Kaplan‐Meier curves for the combined endpoint of death, new AMI, stroke, or new revascularization. Abbreviations: AMI, acute myocardial infarction
Figure 3
Figure 3
Kaplan‐Meier curves for the combined endpoint of death, new AMI, stroke, or new revascularization. (A) Patients treated due to STEMI; (B) patients treated due to NSTEMI/UA. Abbreviations: AMI, acute myocardial infarction; NSTEMI, non–ST‐segment elevation myocardial infarction; STEMI, ST‐segment elevation myocardial infarction; UA, unstable angina
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Lincoff AM, Califf RM, Moliterno DJ, et al. Complementary clinical benefits of coronary‐artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. N Engl J Med 1999; 341: 319–327. - PubMed
    1. Blankenship JC, Tasissa G, O' Shea JC, et al; ESPRIT Investigators. Effect of glycoprotein IIb/IIIa receptor inhibition on angiographic complications during percutaneous coronary intervention in the ESPRIT trial. J Am Coll Cardiol 2001; 38: 653–658. - PubMed
    1. Karvouni E, Katritsis DG, Ioannidis JP Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. J Am Coll Cardiol 2003; 41: 26–32. - PubMed
    1. Canadian Cardiovascular Society; American Academy of Family Physicians; American College of Cardiology; American Heart Association; Antman EM, Hand M, Armstrong PW, et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST‐elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in J Am Coll Cardiol. 2008 51: 977]. J Am Coll Cardiol 2008; 51: 210–247. - PubMed
    1. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non‐ST‐elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non‐ST‐Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2008; 51: 974. - PubMed

Publication types

MeSH terms